Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum
Authors
Keywords
Favipiravir, COVID-19, Tandem mass spectrometry, Validation
Journal
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Volume 1176, Issue -, Pages 122768
Publisher
Elsevier BV
Online
2021-05-20
DOI
10.1016/j.jchromb.2021.122768
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
- (2021) Hany M. Dabbous et al. ARCHIVES OF VIROLOGY
- Favipiravir in Therapy of Viral Infections
- (2021) Ryta Łagocka et al. Journal of Clinical Medicine
- CNBP Binds and Unfolds In Vitro G-Quadruplexes Formed in the SARS-CoV-2 Positive and Negative Genome Strands
- (2021) Georgina Bezzi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
- (2021) Katharina Habler et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Pharmacotherapy in COVID-19; A narrative review for emergency providers
- (2020) Nikita Mehta et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
- (2020) Lisheng Wang et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- COVID-19, SARS and MERS: are they closely related?
- (2020) N. Petrosillo et al. CLINICAL MICROBIOLOGY AND INFECTION
- Candidate drugs against SARS-CoV-2 and COVID-19
- (2020) Dwight L. McKee et al. PHARMACOLOGICAL RESEARCH
- COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge
- (2020) Jacek Baj et al. Journal of Clinical Medicine
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Characteristics of SARS-CoV-2 and COVID-19
- (2020) Ben Hu et al. NATURE REVIEWS MICROBIOLOGY
- Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database
- (2020) Rimple Jeet Kaur et al. Infection and Drug Resistance
- DNA vaccines against COVID-19: Perspectives and challenges
- (2020) Marcelle Moura Silveira et al. LIFE SCIENCES
- Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues
- (2020) Maria A. Acquavia et al. TALANTA
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started